Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elbasvir/grazoprevir in children and adolescents with chronic hepatitis C
2015-003006-16Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elbasvir and grazoprevir in hepatitis C virus infection, sponsored by Merck & Co. Primary endpoints: Week 4 AUC0-24, Week 4 Cmax and 2 more. Started Oct 2017; status: completed.
02
Drugs
elbasvirgrazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2015-003006-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003006-16.